Animal models of SARS-CoV-2 transmission

Rory D. de Vries; Barry Rockx; Bart L. Haagmans; Sander Herfst; Marion PG Koopmans; Rik L. de Swart

doi:10.1016/j.coviro.2021.06.007

Animal models of SARS-CoV-2 transmission

Rory D. de Vries, Barry Rockx, Bart L. Haagmans, Sander Herfst, Marion PG Koopmans, Rik L. de Swart^*

^*Corresponding author for this work

Virology

Research output: Contribution to journal › Review article › Popular

22 Citations (Scopus)

Abstract

SARS-CoV-2 emerged in China as a zoonotic virus in December 2019. The virus proved to be human-to-human transmissible and its global spread resulted in the ongoing COVID-19 pandemic, associated with high morbidity and mortality. Vaccines were developed at an unprecedented speed and proved to be efficacious in preventing disease, but it remains to be determined if vaccines are able to interrupt transmission. Moreover, virus variants of concern continue to emerge that appear more transmissible and/or less sensitive to virus-specific immune responses. Here, we briefly review the role of animal models in assessing prophylactic and therapeutic options to interrupt SARS-CoV-2 transmission.

Original language	English
Pages (from-to)	8-16
Number of pages	9
Journal	Current Opinion in Virology
Volume	50
DOIs	https://doi.org/10.1016/j.coviro.2021.06.007
Publication status	Published - 1 Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.coviro.2021.06.007

Cite this

@article{0b0dca32e0d64796955821704067ca10,

title = "Animal models of SARS-CoV-2 transmission",

abstract = "SARS-CoV-2 emerged in China as a zoonotic virus in December 2019. The virus proved to be human-to-human transmissible and its global spread resulted in the ongoing COVID-19 pandemic, associated with high morbidity and mortality. Vaccines were developed at an unprecedented speed and proved to be efficacious in preventing disease, but it remains to be determined if vaccines are able to interrupt transmission. Moreover, virus variants of concern continue to emerge that appear more transmissible and/or less sensitive to virus-specific immune responses. Here, we briefly review the role of animal models in assessing prophylactic and therapeutic options to interrupt SARS-CoV-2 transmission.",

author = "{de Vries}, {Rory D.} and Barry Rockx and Haagmans, {Bart L.} and Sander Herfst and Koopmans, {Marion PG} and {de Swart}, {Rik L.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = oct,

day = "1",

doi = "10.1016/j.coviro.2021.06.007",

language = "English",

volume = "50",

pages = "8--16",

journal = "Current Opinion in Virology",

issn = "1879-6257",

publisher = "Elsevier",

}

TY - JOUR

T1 - Animal models of SARS-CoV-2 transmission

AU - de Vries, Rory D.

AU - Rockx, Barry

AU - Haagmans, Bart L.

AU - Herfst, Sander

AU - Koopmans, Marion PG

AU - de Swart, Rik L.

PY - 2021/10/1

Y1 - 2021/10/1

N2 - SARS-CoV-2 emerged in China as a zoonotic virus in December 2019. The virus proved to be human-to-human transmissible and its global spread resulted in the ongoing COVID-19 pandemic, associated with high morbidity and mortality. Vaccines were developed at an unprecedented speed and proved to be efficacious in preventing disease, but it remains to be determined if vaccines are able to interrupt transmission. Moreover, virus variants of concern continue to emerge that appear more transmissible and/or less sensitive to virus-specific immune responses. Here, we briefly review the role of animal models in assessing prophylactic and therapeutic options to interrupt SARS-CoV-2 transmission.

AB - SARS-CoV-2 emerged in China as a zoonotic virus in December 2019. The virus proved to be human-to-human transmissible and its global spread resulted in the ongoing COVID-19 pandemic, associated with high morbidity and mortality. Vaccines were developed at an unprecedented speed and proved to be efficacious in preventing disease, but it remains to be determined if vaccines are able to interrupt transmission. Moreover, virus variants of concern continue to emerge that appear more transmissible and/or less sensitive to virus-specific immune responses. Here, we briefly review the role of animal models in assessing prophylactic and therapeutic options to interrupt SARS-CoV-2 transmission.

UR - http://www.scopus.com/inward/record.url?scp=85110169099&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2021.06.007

DO - 10.1016/j.coviro.2021.06.007

M3 - Review article

C2 - 34256352

AN - SCOPUS:85110169099

SN - 1879-6257

VL - 50

SP - 8

EP - 16

JO - Current Opinion in Virology

JF - Current Opinion in Virology

ER -

Animal models of SARS-CoV-2 transmission

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this